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Abstract
Background: The whole-blood interferon-gamma release assay (IGRA) is recommended in some
settings as an alternative to the tuberculin skin test (TST). Outcomes from field implementation of
the IGRA for routine tuberculosis (TB) testing have not been reported. We evaluated feasibility,
acceptability, and costs after 1.5 years of IGRA use in San Francisco under routine program
conditions.
Methods: Patients seen at six community clinics serving homeless, immigrant, or injection-drug
user (IDU) populations were routinely offered IGRA (Quantiferon-TB). Per guidelines, we
excluded patients who were <17 years old, HIV-infected, immunocompromised, or pregnant. We
reviewed medical records for IGRA results and completion of medical evaluation for TB, and at
two clinics reviewed TB screening logs for instances of IGRA refusal or phlebotomy failure.
Results: Between November 1, 2003 and February 28, 2005, 4143 persons were evaluated by
IGRA. 225(5%) specimens were not tested, and 89 (2%) were IGRA-indeterminate. Positive or
negative IGRA results were available for 3829 (92%). Of 819 patients with positive IGRA results,
524 (64%) completed diagnostic evaluation within 30 days of their IGRA test date. Among 503
patients eligible for IGRA testing at two clinics, phlebotomy was refused by 33 (7%) and failed in 40
(8%). Including phlebotomy, laboratory, and personnel costs, IGRA use cost $33.67 per patient
tested.
Conclusion: IGRA implementation in a routine TB control program setting was feasible and
acceptable among homeless, IDU, and immigrant patients in San Francisco, with results more
frequently available than the historically described performance of TST. Laboratory-based diagnosis
and surveillance for M. tuberculosis infection is now possible.
Background
Providers in the United States and Europe have for many
years relied on the tuberculin skin test (TST) to detect
infection with Mycobacterium tuberculosis in patients. The
limitations of the TST are well documented, including
placement variability, inter-reader variability, boosting,
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vaccinated with bacille Calmette Guerin (BCG) or with
non-tuberculosis mycobacterial (NTM) infection. [1,2]
Patients may find the test inconvenient because they must
return in 48–72 hours for result reading and interpreta-
tion. TST use poses operational challenges, such as the
training and retraining of numerous health care workers
in proper test performance and interpretation. Patients
and providers alike may have low confidence in test
results, particularly when interpreting results for patients
with prior BCG vaccination. Furthermore, the decentral-
ized nature of the TST makes collection of valid popula-
tion-based surveillance data for M. tuberculosis infection
very challenging, particularly as latent TB infection (LTBI)
is not a reportable medical condition in most areas.
Laboratory-based testing for M. tuberculosis infection
could in theory overcome the technical and operational
limitations of the TST, but until recently no such test was
commercially available in the United States. However, in
November 2001, the United States Food and Drug
Administration approved the first blood assay for Myco-
bacterium tuberculosis for use as an aid in the diagnosis of
M. tuberculosis infection. Commercially known as the
QuantiFERON®-TB test (Cellestis International, Carnegie,
Australia), this assay provides information about patients'
cell-mediated immune response to M. tuberculosis by
measuring interferon-γ produced in whole blood after
incubation with purified protein derivative (PPD) from
M. tuberculosis [3] Use of this interferon-γ release assay
(IGRA) for detection of M. tuberculosis infection has been
reported in several research studies and in small hospital-
or laboratory-based implementations [4-8].
No field experiences using blood assays for M. tuberculosis
testing in TB programs have been reported, and many
unanswered questions remain about use under routine
programmatic conditions. In November 2003, the San
Francisco Department of Public Health (SFDPH) began
limited implementation of IGRA use, substituting an
IGRA for the TST in a TB testing and prevention program.
SFDPH community health centers have routinely
screened patients for TB using risk factor-based testing in
accordance with CDC guidelines for targeted testing and
treatment of LTBI. [9] Six clinical sites serving distinct
patient populations with TB risk factors were selected to
switch from the TST to IGRA as the routine test for infec-
tion with M. tuberculosis. These sites included two clinics
serving a primarily homeless population (homeless clin-
ics), two immigrant and refugee screening clinics (immi-
grant clinics), the county hospital methadone clinic, and
the county TB clinic. TB testing procedures at these clinical
sites were revised to specify that the IGRA was the default
TB test offered to patients in whom TB testing was indi-
cated.
We sought to evaluate 1) the feasibility of routine IGRA
use for TB testing, as measured by valid IGRA results and
completion of subsequent evaluation of patients with
positive IGRA results, 2) the acceptability of blood assays
for M. tuberculosis to patients, as measured by phlebotomy
refusal, and 3) the costs of implementing IGRA testing for
the health care system in San Francisco.
Methods
Program description
The San Francisco Department of Public Health (SFDPH)
operates a network of 12 community health centers
throughout San Francisco and a dedicated tuberculosis
(TB) clinic at the county hospital. SFDPH community
health centers have routinely screened patients for TB
using risk-factor based screening in accordance with Cent-
ers for Disease Control and Prevention (CDC) guidelines
for targeted testing and treatment of TB. [10] Briefly,
patients identified with medical or epidemiologic risk fac-
tors for TB infection (including HIV infection, diabetes
mellitus, current or planned immunosuppressive medica-
tions, homelessness, injection drug use, or immigration
within 5 years from a TB-endemic country) were screened
for TB at health centers by symptom review and a tubercu-
lin skin test (TST). If either symptom screen or TST results
were positive, then patients were referred to the TB clinic
for chest radiograph (CXR), medical evaluation to exclude
active TB, and consideration for treatment of latent tuber-
culosis infection (LTBI). Patients with prior treatment for
TB infection or prior positive TST results were not evalu-
ated by TST, but instead were directly referred to TB clinic
for CXR and medical evaluation. If patients with positive
TST results did not arrive at the SFDPH TB clinic within 30
days of referral, SFDPH routinely notified the referring
clinic of the incomplete evaluation, and requested that the
patient be again referred for medical evaluation. This ret-
rospective program evaluation was undertaken with the
ethical approval of the Centers for Disease Control and
Prevention.
Implementation of whole-blood interferon-gamma assay 
screening
Six clinical sites serving distinct patient populations with
TB risk factors were chosen to switch from the TST to a
blood assay for Mycobacterium tuberculosis (BAMT) as the
routine test for TB infection. The BAMT chosen for use was
the Quantiferon®-TB (Cellestis International, Carnegie,
Australia), an interferon gamma release assay (IGRA)
which at the time was the only BAMT approved for use by
the Food and Drug Administration. These sites included 2
clinics serving a primarily homeless population (home-
less clinics), 2 immigrant and refugee screening clinics
(immigrant clinics), the county hospital methadone
clinic, and the county TB clinic. TB screening procedures
at these clinical sites were revised so that the IGRA was thePage 2 of 8
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with CDC guidelines for the Quantiferon®-TB assay, [3]
providers were instructed to use the IGRA for all patients
who were >17 years of age, not a contact to a TB case, not
pregnant, and not immunocompromised; if the patient
had any of these IGRA exclusion criteria, a TST was used.
Because of same-day specimen processing requirements
for the IGRA, providers were also instructed to use the TST
instead if patients refused phlebotomy, if phlebotomy
yielded less than 4 ml blood, or if the daily courier had
already taken specimens to the laboratory. Patients were
asked to return to clinic after 3 working days for IGRA
results; those with positive IGRA results were managed in
the same manner as patients with positive TST results, i.e.
referred to TB clinic for radiograph and medical evalua-
tion.
Laboratory methods
Specimens were processed and evaluated by IGRA accord-
ing to manufacturer instructions[11] At the time of this
evaluation, this was the only IGRA for tuberculosis screen-
ing commercially available in the United States. Speci-
mens were sent via courier to the laboratory for processing
on the same day as phlebotomy. Briefly, 1 ml aliquots of
heparinized whole-blood were incubated with 3 drops
saline (nil), phytohemaglutinin (mitogen control), 5 ug/
ml PPD from M. tuberculosis (tuberculin), and 5 ug/ml
PPD from M. avium (avian sensitin). Specimens were
incubated for 12 hours at 37°C. Plasma was collected and
IFN-G concentration was determined by ELISA provided
with the kit.
IGRA results were interpreted based on the proportion of
IFN-G released in response to tuberculin, compared with
mitogen, accounting for the background IFN-G level in
the nil control samples [(tuberculin-nil)/(mitogen-nil) ×
100 = percentage tuberculin response]. The percentage
avian difference was calculated as [(avian-nil) - (tubercu-
lin-nil)/(mitogen-nil) × 100]. An IGRA result was indeter-
minate if the (mitogen-nil) IFN-G level ≤ 1.5 IU. An IGRA
result was negative if the (mitogen-nil) was ≥ 1.5 IU IFN-
G and the percentage tuberculin response ≤ 15%. An IGRA
result was positive if the following criteria were met: 1)
(mitogen-nil) and (tuberculin-nil) ≥ 1.5 IU IFN-G, 2) per-
centage tuberculin response ≥ 15%, and 3) percentage
avian difference ≤ 10%. Although manufacturer guide-
lines stipulated a 'conditional positive' interpretation for
low-risk individuals, conditional positive results were not
separately reported because SFDPH did not screen low-
risk individuals. [3]
Cohort review of patients with IGRA results
IGRA results from patients screened from November 2003
– February 2005 were reviewed. All patients for whom a
specimen was received in the laboratory were included,
even if that specimen could not be tested for technical rea-
sons. Patient results were stratified by age and screening
site. As the evaluation used data collected under routine
programmatic conditions, health information beyond age
and epidemiologic TB risk factor was not collected. We
included only the first test result for each patient in the
cohort, as some patients were screened more than once
during the 15-month evaluation period. In the small sub-
set of patients with IGRA results who were suspected of
having active TB after their TB clinic medical evaluation
(American Thoracic Society classification TB-5), [2] we
evaluated the accuracy of the IGRA for the diagnosis of
active TB. We reviewed TB clinic medical records to deter-
mine the outcome of patients classified as TB suspects
who had IGRA results reported within 2 weeks of initia-
tion of anti-TB treatment. Standard case definitions for a
report of a verified case of tuberculosis (RVCT) were used.
[12] Medical records were also reviewed for available TST
results from within 30 days of the IGRA date
Acceptability of blood-test based TB screening
To evaluate acceptability, we reviewed TB screening logs
that had been implemented at 2 of the 6 clinic sites. The
TB screening logs recorded the experience of all patients
consecutively screened for TB by IGRA or TST at a home-
less clinic from May through November 2004 (n = 406),
and at a refugee clinic from June through December 2004
(n = 145). This patient population only partially over-
lapped with the cohort of patients with IGRA test results,
as it also included patients evaluated by TST, hence has
been presented as a parallel but separate evaluation.
All patients seen for TB screening at these clinics were rou-
tinely offered IGRA unless they belonged to populations
for whom the IGRA was not recommended. Patients who
were not offered IGRA, who refused phlebotomy for
IGRA, or who had unsuccessful phlebotomy were offered
TST instead. Logs were reviewed to identify instances of TB
screenings where patients refused phlebotomy for IGRA,
had unsuccessful phlebotomy for IGRA, or fell into an
IGRA exclusion category. Patients with positive TST, IGRA,
or symptom review results from these clinic were rou-
tinely referred to the SFDPH TB Clinic for further medical
evaluation. We reviewed TB clinic medical records to
determine the proportion of these patients with positive
IGRA results who had a CXR and medical evaluation
within 30 days of their IGRA test date.
Cost assessment
We conducted a cost assessment from the perspective of
the health care system in San Francisco to quantify the
expenditures necessary to implement interferon-gamma
assay TB screening. All clinical and laboratory supplies
needed to perform the test were measured. Because the
test is performed most efficiently in batches of 20  speci-Page 3 of 8
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cisco, we  recorded the minimum time necessary for
laboratory staff to complete  testing on one batch of spec-
imens. Laboratory supplies used for a single batch of 20
patient specimens was recorded. Staff costs for clinical and
laboratory staff were calculated using SFDPH hourly sal-
ary tables for mid-grade employees, with 26% added to
account for employee benefits. Training sessions for clini-
cal staff were not included in costs, as this was judged to
be a one-time start-up activity of the TB control program.
We used retail costs for all supplies including the commer-
cial kits for the interferon gamma assay; though SFDPH
sometimes gets discounts for supplies through vendors,
these discounts are variable. Shipping charge costs were
drawn from a SFDPH contract with a local courier service.
Laboratory equipment costs were assigned a per-patient
cost by determining the proportion of daily time used for
a batch of 20 specimens, with 3% linear discounting
applied over an estimated 10-year equipment lifespan.
Results
Results of IGRA testing
From November 2003 through February 2005, SFDPH
evaluated 4143 unique patients by IGRA at six clinic sites.
The median patient age was 43.4 years (range 2–100); this
included 79 (1.9%) patients <18 years old, despite the rec-
ommendation that patients under 18 not be tested.
Among the 4143 patients evaluated by IGRA, 225 (5.4%)
had specimens rejected by the laboratory because of insuf-
ficient blood, clotted blood, or receipt after cut-off time
for daily specimen processing. Among the remaining
3918 specimens tested, 2600 (66%) were submitted by
the two homeless clinics.
Of the 3918 specimens tested results were positive in 819
(21%), negative in 3010 (77%), and indeterminate in 89
(2%). (Table 1) Patients tested at the methadone clinic
were more likely to have indeterminate results than those
at all other sites combined (relative risk [RR] 3.5, 95%
confidence interval (CI) 2.0–6.1). IGRA results from 819
(21%) were positive. A higher proportion of patients had
positive IGRA results at the immigrant and refugee clinics
(34%) and the TB clinic (33%) than at the homeless clin-
ics (16%) or methadone clinic (17%). Among the 819
patients with positive IGRA results, 524 (64%) subse-
quently completed diagnostic evaluation at the SFDPH TB
Clinic within 30 days of IGRA testing, 575 (70%) within
60 days, and 593 (72%) within 90 days (Table 2). A
higher proportion of patients tested at the TB clinic com-
pleted diagnostic evaluation than patients seen at any
other clinic site. We were unable to compare the evalua-
tion outcomes of patients tested by TST, as TST results
have never been routinely reported in San Francisco.
During the evaluation period, SFDPH identified a total of
352 patients as suspected of having TB (ATS classification
Table 1: Results from routine testing of patients with risk factors for M. tuberculosis infection using a PPD-based whole blood 
interferon-γ release assay (IGRA), stratified by testing site. San Francisco, November 2003 – February 2005
Homeless Clinics 
(n = 2)
TB Clinic Immigrant & Refugee 
(n = 2)
Methadone Clinic Total
IGRA Result n (%) n (%) n (%) n (%) N (%)
Positive 411 (16) 213 (33) 164 (34) 31 (17) 819 (21)
Negative 2148 (82) 419 (64) 303 (63) 140 (76) 3010 (77)
Indeterminate 41 (2) 21 (3) 14 (3) 13 (7) 89 (2)
Total tested 2600 642 481 184 3918
Table 2: Cumulative proportion of patients with positive IGRA results with documented completion of chest radiograph and medical 
evaluation, by testing site. Days counted from blood draw date.
Homeless Clinics 
(n = 2)
TB Clinic Immigrant & Refugee 
(n = 2)
Methadone Clinic Total
Evaluation completed by n = 411 (%) n = 212 (%) n = 164 (%) n = 31 (%) N = 818 (%)
30 days 245 (60) 165 (78) 94 (57) 19 (61) 524 (64)
60 days 267 (65) 181 (85) 105 (64) 21 (68) 575 (70)
90 days 274 (67) 191 (90) 107 (65) 21 (68) 593 (72)Page 4 of 8
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30 days prior to and until 14 days after the initiation of
anti-TB treatment. Nine (45%) of the 20 TB suspects with
IGRA results were diagnosed with a verified case of TB,
including seven laboratory-confirmed and two clinically
verified TB cases. Although this sample was not large
enough to allow assessment of IGRA accuracy for TB diag-
nosis, among the seven laboratory-confirmed TB cases,
two had negative IGRA results. No TST results were avail-
able for comparison.
Acceptability of blood test-based TB testing
From May through November 2004, one homeless clinic
examined 406 unique patients (Table 3); 31 (8%)
belonged to populations for whom IGRA was not recom-
mended, and were offered TST instead. Among the 375
eligible for IGRA testing, 312 (83%) had a specimen sent
for IGRA testing; phlebotomy failed in 33 (9%) and was
refused by 30 (8%). In the 312 patients with IGRA per-
formed, 310 (99%) had interpretable (i.e., positive or
negative) results. A historical comparison of the TST read-
ing return rate was available from the routine records of
the same clinic. Before IGRA implementation in 2003,
1523 (88%) of 1734 patients tested by TST had returned
for TST reading within 4 days. Of note, this clinic serves
clients who frequently needed "TB clearance" for home-
less shelters, and has a historically high TST return rate.
From June through December 2004, the refugee clinic
examined 145 unique patients; 17 (12%) belonged to
populations for whom IGRA was not recommended, and
these patients were offered TST instead. Among the 128
patients eligible for IGRA, phlebotomy failed in seven
(5%) and was refused by three (2%). In the 113 patients
with IGRA performed, 108 (96%) had interpretable
results. From this clinic, no historical information about
patient return for TST reading was available for compari-
son.
Cost assessment
We estimated the cost to the health care system in San
Francisco per patient tested by IGRA as $33.67 (Table 4).
Table 3: Acceptability of blood-based TB test at a homeless clinic and a  refugee-screening clinic, San Francisco, May-December 2004. 
*Patients  less than 18 years old, HIV-infected, immunocompromised, or pregnant  were ineligible for IGRA. **Seen at SFDPH TB 
clinic for medical  evaluation and chest radiograph within 30 days of IGRA date.
Homeless Clinic n (%) Refugee Clinic n (%) Total N (%)
Tested by TST or IGRA 406 145 551
IGRA Ineligible* 31 (8) 17 (12) 48 (9)
IGRA eligible 375 (100) 128 (100) 503 (100)
IGRA performed 312 (83) 113 (88) 425 (84)
After lab time cut-off 0 (0) 5 (4) 5 (1)
Phlebotomy refused 30 (8) 3 (2) 33 (7)
Phlebotomy failed 33 (9) 7 (5) 40 (8)
TST attempted 94 (100) 32 (100) 126 (100)
Returned for reading 68 (72) 32 (100) 100 (79)
Positive IGRA results 53 (100) 50 (100) 103 (100)
Successfully evaluated** 42 (79) 34 (68) 76 (74)
Table 4: Health care system costs for use of whole-blood interferon-γ assay (QuantiFERON-TB®) for testing for M. tuberculosis 
infection. Total costs incurred for batch of 20 patients tested (2004$). Equipment usage based on time used during assay, with 10-year 
estimated lifespan for all laboratory equipment. Laboratory staff costs based on hourly salary plus benefits cost for mid-grade staff.
Task Group Resources Used Units Used per Batch of 20 
Patients
Cost Per Patient Tested ($)
Phlebotomy Nursing staff time 1.34 hours (4 minutes per patient) 3.06
Supplies 20 tubes and needles 2.20
Shipping Courier service 1 daily courier trip ($10) 0.50
Laboratory Commercial kits 0.5 commercial kits 16.50
Consumables Laboratory supplies 2.39
Equipment usage Orbital rocker, ELISA washer and 
reader, incubator, hood, computer
0.11
Clerical staff 0.66 hours 0.77
Clinical lab scientist 4.16 hours 8.14
Total $33.67Page 5 of 8
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ratory, with a smaller proportion incurred during phlebot-
omy and shipping of specimens. Almost half of the total
cost was the commercial kit itself, but $8.91 (26%) of the
per-patient cost was attributable to laboratory staff costs.
Owing to the pipetting of variable volumes and result
interpretation required for the commercial test, federal
laboratory regulations indicate that a clinical laboratory
scientist perform the test instead of a lower salary rate lab-
oratory technician.
Discussion
These are the first reported operational outcomes of pro-
gram efforts to switch from the TST to a blood assay for M.
tuberculosis. In San Francisco, TB testing using the IGRA
was feasible and acceptable under routine programmatic
conditions in several different clinics. We tested 4143
patients by IGRA and obtained usable results on 3829
(92%). Indeterminate results were uncommon (2%). The
PPD-based IGRA used during this time period has since
been superseded by newer tests using Mycobacterium tuber-
culosis-specific region of difference 1 (RD1) antigens (such
as early secretory antigenic target 6 and culture filtrate pro-
tein 10) for T cell stimulation. Available evidence suggests
that these RD1-based IGRA tests are more specific than the
TST, and have similar or slightly higher sensitivity in most
situations[13] But the operational experiences we describe
remain relevant to any public or occupational health pro-
gram currently using the TST and considering use of a
blood assay for M. tuberculosis.
IGRA results were available to the TB program on 92% of
persons tested, representing a likely improvement in TB
testing outcomes compared to TST. This outcome com-
pares favorably to the reported return rate for TST reading
in similar patient populations in other cities, including
84% at a needle-exchange program in Baltimore, 64% at
a public health program in Atlanta, and 47% in a street
outreach program for drug users in Long Beach. [14-16]
Since results are available on most patients tested by
IGRA, program resources may be directed to improving
follow-up of patients with positive IGRA results. Ample
room remains for follow-up improvement; among the
819 patients with positive results, subsequent medical
and radiograph evaluations were completed within 30
days in 524 (64%). Collection of comparable outcomes
for TST was not possible from program data in San Fran-
cisco, since no surveillance system existed for TST results.
Surveillance for new instances of infection with M. tuber-
culosis has been previously attempted in San Francisco,
but failed due to the decentralized and subjective nature
of the TST and to the large resource investment required
to maintain surveillance system function in hundreds of
testing locations throughout the city. Laboratory-based
testing allowed us to obtain accurate data for surveillance
of LTBI from these IGRA pilot sites, including both
denominator data for patients tested and longitudinal
data alerting SFDPH to instances of newly detected M.
tuberculosis infection, including the occurrence of IGRA
'conversion', i.e. positive results in a patient with previ-
ously negative results. Furthermore, the use of a labora-
tory-based test improved information availability for
community providers and likely reduced duplicate test-
ing, as previous results were available via an electronic
laboratory result reporting system accessible to many
community clinics. In San Francisco, since March 2005 a
newer version of the IGRA (QuantiFERON-TB Gold®, Cell-
estis International), which uses RD-1 antigens for leuko-
cyte stimulation, has been available to all SFDPH clinics
and key community organizations providing services to
homeless and immigrant populations. Through wider use
of this newer IGRA, we have essentially created a labora-
tory-based surveillance system for infection with M. tuber-
culosis, with reliable reporting of newly detected instances
of infection with M. tuberculosis among key populations
such as the homeless, IDUs, and new immigrants. This
advance in TB surveillance capacity may allow SFDPH to
more accurately target case finding and prevention activi-
ties in the future.
Phlebotomy for IGRA-based TB testing proved acceptable
among a majority of patients at both a homeless clinic
and a refugee clinic. Phlebotomy refusal was uncommon
(8%), and phlebotomy failed in only 8% of patients with
a high prevalence of intravenous drug use. At the home-
less clinic, among patients tested by IGRA, a positive or
negative result was obtained in 99%, which is greater than
the proportion of patients who returned for TST reading at
that particular site prior to IGRA implementation (88%).
IGRA implementation cost the health care system in San
Francisco approximately $33.89 per patient tested, most
of which (83%) was incurred by the laboratory. This cost
assessment includes only measurable direct costs of phle-
botomy, specimen transport, and laboratory specimen
processing. Assuming all other costs remain the same, we
have projected that the more-expensive RD1-based IGRA,
QuantiFERON®-TB Gold, will cost approximately $37.39
per patient tested. In comparison, the Center for Medicare
Services has estimated the cost of the TST to be $9.79. [17]
Despite this lower per-test cost for TST, several factors
such as differences in test specificity, patient time require-
ments, and the potential to lower the laboratory cost for
IGRA through automation raise the possibility that the
IGRA may be the more cost-effective test. Future cost-
effectiveness analysis comparing IGRA and TST use in TB
testing will be necessary, and should include potential
cost savings from improved patient evaluation rates andPage 6 of 8
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results.
Several operational challenges were noted during IGRA
implementation. Same-day processing for specimens
necessitated early and often inconvenient cut-off times for
specimen collection, as well as use of a courier service.
Patients attending afternoon or evening clinics were
forced to return another morning for IGRA testing or to
have a TST. Future versions of the IGRA that might allow
more flexible timing of specimen collection and transport
would mitigate this challenge. The occasional occurrence
of discordant IGRA and TST results proved time-consum-
ing for patients and providers to manage. Programs
implementing IGRA should establish guidelines to help
providers manage such events.
Our operational evaluation has several limitations. We
did not randomize patients or sites to TST or IGRA. A ran-
domized study would yield a more accurate comparison
of acceptability and testing outcomes. Our evaluation was
not intended to evaluate IGRA concordance with TST
results; studies addressing that question have been
reported elsewhere[13] In accordance with CDC guide-
lines we excluded many patient populations such as chil-
dren and HIV-infected persons from IGRA, but
operational outcomes may differ in those groups. Patients
with positive IGRA results may not have responded to
SFDPH attempts to contact them, and instead may have
been evaluated by private providers. Hence we may have
underestimated the proportion of patients who were
tested for TB after receiving positive IGRA results. Our cost
estimates are specific for the health care system in San
Francisco, and should not be considered generalizable.
We did not collect data about costs incurred by patients,
which may significantly differ between IGRA and TST. We
used phlebotomy refusal to substitute for specific ques-
tions to patients about TST or IGRA preference. In our
evaluation we did not extend data collection to include
completion of treatment for LTBI, which would be the
optimal outcome measure for feasibility, but may vary
widely by setting and patient population. Lastly, our eval-
uation included only the first-generation PPD-based
IGRA, but the use of new antigens should not necessarily
affect programmatic outcomes such as feasibility and
acceptability, which are likely to be common among
blood assays for M. tuberculosis.
Conclusion
IGRA-based TB testing was successfully implemented and
well accepted under routine programmatic conditions.
No adverse programmatic outcomes were identified. Lab-
oratory-based surveillance for TB infection now appears
possible. Programs considering switching from TST to
IGRA may expect to realize benefits in completion rates of
TB testing, reporting of results, and surveillance capacity.
With improved RD1-based IGRA tests offering higher spe-
cificity than TST, programs may find that the avoidance of
unnecessary testing and treatment of patients with false-
positive TST results yields additional public health bene-
fits.
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